Background: Neutrophils are central to the initiation, progression and resolution of inflammatory diseases such as RA. We have previously shown that neutrophils from RA patients have a gene expression signature indicating activation in vivo by interferons (IFNs), and higher expression of IFN-response genes is associated with a good response to TNFi therapy. The aim of this work was to investigate the functional effects of IFNs on neutrophils in vitro both (i) alone, and (ii) in combination with inflammatory cytokines. Methods: Neutrophils were isolated from peripheral blood of healthy controls and incubated with Type-I IFN (IFNa) or Type-II IFN (IFNg) at a range of concentrations in the absence or presence of GM-CSF and TNFa. Apoptosis was measured at 18h by flow cytometry using annexin V/PI; respiratory burst was measured at hourly intervals up to 5h using luminol-enhanced chemiluminescence after stimulation with fMLP or PMA; changes in protein expression and phosphorylation were measured by Western blotting; changes in gene expression were measured by RNA-Seq (Illumina). Results: Neutrophils stimulated with IFNs in vitro underwent rapid phosphorylation of STAT proteins (5-30 min), activation of IFNresponse genes (1h), and priming of the respiratory burst (3h), but only Type-II IFN delayed apoptosis, measured at 18h (unstimulated 58.6% AE 0.6, IFNg 41.4% AE 4.1, P < 0.05). Addition of IFNs to neutrophil suspensions containing GM-CSF or TNFa had a profound dose-dependent effect on the function of the inflammatory cytokines. Type-I IFNs abrogated the protective effect of GM-CSF on neutrophil apoptosis at 18h (GM-CSF 25.6% AE 2.7, GM-CSF þ IFNa 49.5% AE 1.2, P < 0.01), whereas Type-II IFNs enhanced the anti-apoptotic effect of TNFa (TNFa 42.3% AE 3.3, TNFa þ IFNg 27.4% AE 1.2, P < 0.05) and sustained the TNFa priming effect on the respiratory burst for up to 4h (P < 0.01). Type-I and Type-II IFNs enhanced STAT3 phosphorylation by GM-CSF, and altered the activation kinetics of ERK and AKT by GM-CSF. Type-I IFN enhanced AKT phosphorylation in TNFa stimulated neutrophils. Conclusion: IFNs profoundly alter the functional effects of inflammatory cytokines on neutrophils in vitro. This may have important consequences in vivo during therapy with biologic drugs such as TNFi. The complexity and heterogeneity of inflammatory diseases such as RA, where different cytokines dominate or act synergistically to perpetuate systemic inflammation, may explain why some patients respond better to certain biologic therapies than others. We are currently investigating the consequences of TNFi (Infliximab) and JAKi (Tofacitinib) on neutrophils stimulated in vitro with IFNs, GM-CSF and TNFa. Disclosure statement: The authors have declared no conflicts of interest. Background: A recent genome wide association study identified the variant rs26232 in the first intron of an uncharacterized gene C5orf30 as a RA susceptibility variant1. In addition, it has been associated with severity of radiological joint damage suggesting a role in tissue breakdown2. To date there is no function assigned for C5orf30 and neither the gene or protein show homology to any known functional sequences. However, C5orf30 is highly conserved in chimpanzee, dog, cow, mouse, chicken, and zebrafish (orthologs). The aim of this study is to determine the biological role of C5orf30 in RA synovial fibroblast. Methods: Immunohistochemistry on synovial samples was used to determine expression of C5orf30 including co-localization using antibodies to macrophages (CD68), fibroblasts (5B5), T (CD3) & B (CD19) cells. Real time PCR and western blotting were used to examine C5orf30 transcript and protein levels in fibroblast-like synovial cells (FLS stimulated with TNF & hypoxia). To investigate gene function siRNA was used to knockdown (KD) either C5orf30 or a non-targeting control (NTC) in synovial FLS in vitro. After knockdown cell viability was assessed by annexin V/propidium iodide staining. Cell invasion and migration were assessed using matrigel invasion and scratch assays and gene expression changes were assessed using an Illumina BeadChip Array. Results: Confocal microscopy revealed C5orf30 to be strongly expressed in both the nuclear and cytoplasmic compartment of RA synovial lining cells including macrophages and fibroblasts, but not T & B cells. C5orf30 was undetectable in arthroscopy sections obtained from OA or control synovium. C5orf30 was expressed in FLS and was found to be up-regulated by hypoxia (8-fold) and down-regulated by TNF (0.5-fold). We found that C5orf30KD compared with the NTC increased the number of invading FLS using the Matrigel invasion assay (P ¼ 0.01) and increased FLS migration using a scratch assay (P ¼ 0.02) (n ¼ 6). Gene profiling studies suggest that multiple gene sets involved in cell migration, adhesion, angiogenesis, and immune and inflammatory pathways were significantly modified following C5orf30KD. Conclusion: C5orf30 knockdown increased FLS migration and invasion into matrigel suggesting C5orf30 is negatively regulating cellular invasion. Together this identifies a potentially novel pathway mediating tissue damage in RA. We are currently performing proteomic analysis and animal studies in order to work out the biology of this important marker in the pathogenesis and severity of RA. Disclosure statement: The authors have declared no conflicts of interest. Background: IL-17 producing T helper 17 (Th17) cells are a subset of pro-inflammatory CD4 T cells implicated in a number of inflammatory arthritides including the spondyloarthritides (SpAs). AS, the commonest SpA, is genetically associated with HLA-B27 (B27) and genes which regulate IL17 production, including the IL23 receptor (IL23R). Previously we have shown that B27 can be expressed at the surface of antigen presenting cells (APC) both as classical b2microglobulin-associated heterotrimeric and b2microglobulin-free disulphidebonded heavy chain homodimers. KIR3DL2þ expressing CD4 T cells are expanded in the peripheral blood of individuals with AS and account for the majority of the increase in IL17 production by CD4 T cells and the majority of CD4 T cells expressing IL23 receptor compared with disease and healthy controls. We sought to determine the molecular mechanism of increased IL23R and IL17 expression by the KIR3DL2 CD4 T cell subset in SpA patients. Methods: We compared the production of IL17 and other cytokines by ELISA by naïve CD4 T cells activated with superantigen and antigen presenting cells (APC) expressing B27 dimers (LBL.721.220(220) B27 and LB1.721(221)221B27) or control HLA-class I (220B7 and 220B8 or 221B7 and 221B35). We also studied expression of Th1 and Th17 (Tbet and RORC/RORgt) by Q-PCR and western blot and KIR3DL2 expression by FACS and western blot. We compared expression of activation (OX40 and CD69), Th17 phenotypic markers (IL23R, IL1R) and chemokine receptor (CCR6 and CCR9) by FACS staining of circulating and synovial T cells form B27 þ SpA patients, and circulating T cells from B27þ and B27-healthy controls and RA patients. 
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